Equities

VCNX

US9186403013

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
5.83 ^USD	-1.70%		+19.96%	-37.36%

Apr. 12	Vaccinex, Inc. announced that it has received $1.75 million in funding	CI
Apr. 02	Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Vaccinex, Inc. announced that it has received $0.320002 million in funding from Vaccinex, L.L.C

September 21, 2023

On September 22, 2023, Vaccinex, Inc. closed the transaction. The company has now issued 136,753 shares of common stock at a purchase price of $2.34 per share for the gross proceeds of $320,002.02. The transaction included participation from returning investor Vaccinex (Rochester), L.L.C.

Latest news about VACCINEXPAR

Vaccinex, Inc. announced that it has received $1.75 million in funding	Apr. 11	CI
Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 02	CI
Vaccinex, Inc. announced that it expects to receive $1.75 million in funding	Mar. 28	CI
Vaccinex, Inc. announced that it has received $1.240737 million in funding from FCMI Parent Co., Vaccinex, L.L.C	Mar. 27	CI
Vaccinex, Inc. announced that it expects to receive $1.240737 million in funding from FCMI Parent Co., Vaccinex, L.L.C	Mar. 26	CI
Vaccinex, Inc. announced that it expects to receive $1.49961 million in funding	Mar. 26	CI
Vaccinex, Inc. Announces Chief Financial Officer Changes, Effective March 14, 2024	Mar. 04	CI
Vaccinex, Inc. Announces Executive Changes, Effective March 14, 2024	Mar. 04	CI
Sector Update: Health Care Stocks Slipping Wednesday Afternoon	Feb. 21	MT
Vaccinex Shares Rise as Company Announces Eight New Deals for Antibody Discovery Platform	Feb. 21	MT
Vaccinex, Inc. Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technology	Feb. 21	CI
Vaccinex, Inc. announced that it expects to receive $3.700126 million in funding	Feb. 06	CI
Vaccinex, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Vaccinex, Inc. Reports Clinical Benefit in Interim Analyses from Two Phase 2 Studies of Pepinemab Combination Treatment At Society for Immunotherapy of Cancer's Annual Meeting	23-10-31	CI
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases	23-10-26	CI
Top Premarket Gainers	23-10-06	MT
Vaccinex Insider Bought Shares Worth $3,000,000, According to a Recent SEC Filing	23-10-05	MT
Vaccinex Insider Bought Shares Worth $509,515, According to a Recent SEC Filing	23-10-05	MT
Top Midday Decliners	23-09-29	MT
Wall Street Set to Open Higher; Personal Consumption Inflation Data Lower Than Expected	23-09-29	MT
Top Premarket Decliners	23-09-29	MT
Vaccinex Prices Offering of Shares, Warrants for Gross Proceeds of About $9.6 Million	23-09-29	MT
Vaccinex's Next Generation ActivMAb®? Technology Published in mAbs	23-09-28	CI
Vaccinex, Inc. to Present Update on PDAC/Pepinemab Study	23-09-27	CI
Vaccinex Reports Groundbreaking Findings At Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer	23-09-26	CI

Chart VACCINEXPAR

Duration

Period

More charts

Company Profile

Vaccinex, Inc. is a clinical-stage biotechnology company. It discovers and develops targeted biotherapeutics to treat diseases with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. Its platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop its lead product candidate pepinemab for the treatment of various diseases and conditions, including cancer and neuroinflammatory and neurodegenerative diseases. Pepinemab's mechanisms of action block the SEMA4D signal and activate innate physiological mechanisms to respond to tumors or tissue injury. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.

Sector

More about the company

Income Statement Evolution

More financial data